Independent educationNo sales. No dosing. Sources on every brief.
The Peptide Field
Menu

Popular starting pointRETA = retatrutide

Seeing RETAeverywhere?Check the evidence.

Start with retatrutide: what its trials found, what remains unknown, and why anything sold online is a different evidence question.

New to peptides? Start with the 3-minute guide

Reviewed July 24, 2026 · No sales · No dosing

RETA, decodedWhat the headlines leave out
  1. What you heard
    “RETA’s results mean it is basically approved.”
  2. What the research contains
    Multiple Phase 3 topline resultsSponsor-reported human outcomesFound
    FDA review and approved labelNo approved retatrutide productNot yet
  3. What we can sayMeaningful late-stage signal.

    Retatrutide is still investigational.

Trial results are not approval—or proof of products sold online.

Read the RETA evidence brief

Source-linked and independently published

20 peptide briefs60 claim checks64 source records

How a claim check works

One claim in. A clearer answer out.

We keep the exact wording visible, find the closest primary record, and stop the conclusion where the evidence stops.

The three-step evidence reviewA claim is separated into its exact wording, matched to the closest primary source, and rewritten as a scoped answer.
  1. 1
    Pin down the claim

    Who, what product, which outcome, and for how long?

  2. 2
    Open the source

    Labels, trials, regulatory records, and primary studies.

  3. 3
    Scope the answer

    What is supported, what is early, and what remains unknown.

Start with a real question

You should not need the scientific vocabulary first.

Begin with the claim you heard. We will show you the evidence terms only when they become useful.

RetatrutideWhat did the retatrutide trial actually show?Supported with scopeBPC-157Does BPC-157 heal tendons in people?Not establishedSemaglutideIs compounded semaglutide the same as an approved product?MisleadingGHK-CuDoes topical GHK-Cu evidence transfer to injections?Misleading
Browse all 60 reviewed claims

Three honest labels

Uncertainty is part of the answer.

A promising study can be real without proving the promise being made online. The label applies to the exact claim and context—not to a molecule forever.

See the public evidence standard
Three evidence labelsEstablished evidence has repeated human outcomes, emerging evidence has a meaningful but limited signal, and insufficient evidence lacks the human outcome support needed for the reviewed claim.
Established
Repeated human outcomes for a defined use.
Emerging
A meaningful human signal with important limits.
Insufficient
The reviewed claim lacks reliable human outcome support.
Evidence stays attached to the studied productA source record connects to the studied formulation and route. Dashed branches toward a different route and a research-labeled product stop before reaching the evidence result.

Source evidence reaches the studied formulation, route, population, and outcome. A shared name does not bridge the gaps.

The product matters

The molecule is not the finished product.

Evidence for one approved or trial product does not automatically transfer to a different route, compounded version, counterfeit, or research-labeled product.

Compare evidence and product certainty

New here?

Build the skill in three short steps.

Start with the biology, learn the evidence shortcuts, then keep the glossary nearby while you explore.

  1. 13 minute startWhat are peptides?

    Meet the basic biology without assuming a chemistry background.

  2. 25 minute skillHow to read a peptide claim

    Separate a mechanism, biomarker, and animal result from a human outcome.

  3. 3Keep nearbyUse the evidence glossary

    Translate trial, product, and regulatory language as you encounter it.

Evidence before enthusiasm

Bring the claim. Leave with its limits.

Educational information only. We do not sell peptides or publish dosing, sourcing, reconstitution, or self-injection instructions.